IMMUNE COMPLEXES (IC) PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF CERTAIN HUMAN DISEASES, SUCH AS SERUM SICKNESS, GLOMERULONEPHITIDES, AND LUPUS ERYTHEMATOSUS, AND ARE ALSO ASSOCIATED WITH RHEUMATOID ARTHRITIS AND A VARIETY OF VASCULITIDES.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$72,851.00
Award Year:
1983
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
494
Agency Tracking Number:
494
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
3005 First Ave., Seattle, WA, 98121
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
EDWARD A. CLARK PH.D.
PRINCIPAL INVESTIGATOR
(206) 624-4300
Business Contact:
() -
Research Institution:
n/a
Abstract
IMMUNE COMPLEXES (IC) PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF CERTAIN HUMAN DISEASES, SUCH AS SERUM SICKNESS, GLOMERULONEPHITIDES, AND LUPUS ERYTHEMATOSUS, AND ARE ALSO ASSOCIATED WITH RHEUMATOID ARTHRITIS AND A VARIETY OF VASCULITIDES. PRESENT TESTS FOR THE DETECTION OF IC RELYON PHYSIOCHEMICAL METHODS OR BIOLOGICALLY BASED ASSAYS WHICHSEPARATE IC FROM FREE ANTIBODY (AB). THE VARIOUS TESTS USEDDO NOT CORRELATE WELL WITH EACH OTHER, HAVE PROBLEMS IN THEIR SENSITIVITY AND/OR SPECIFICITY, AND DO NOT DISTINGUISHIC OF DIFFERENT IMMUNOGLOBULIN ISOTYPES OR SUBCLASSES. THERE IS A REAL NEED FOR A MORE SPECIFIC, SENSITIVE, AND EASY IC ASSAY FOR USE IN DIAGNOSIS, DETERMINING PROGNOSIS, AND MONITORING THERAPEUTIC INTERVENTION. WE PROPOSE TO DEVELOP MONOCLONAL ANTIBODIES (M.AB) SPECIFIC FOR IC WHICH DO NOT REACT WITH EITHER FREE ANTIGEN (AB) OR AB. THESE M.AB. MAY ENABLE IC OF DEFINED ISOTYPES TO BE DETECTED IN A HOMOGENEOUS ASSAY WITHOUT SEPARATION OF BOUND FROM UNBOUND AB. TO DEMONSTRATE THE FEASIBILITY OF THIS APPROACH, WE HAVE SELECTED A MURINE SYSTEM WITH WELL-DEFINED ANTIGENS (HAPTENS) AND WELL-DEFINED ANTIGEN OR HAPTEN-SPECIFIC ANTIBODIES OF DIFFERENT ISOTYPES. BOTH MONOVALENT HAPTEN (DINITROPHENOL, DNP) AND POLYVALENT DNA ANTIGENS WILL BE USED. FIRST, WE WILL DEVELOP M.AB WHICH REACT WITH HAPTEN- CARRIER-ANTIHAPTEN OR DNA-ANTI DNA IMMUNE COMPLEXES, BUT NOT WITH AG OR AB ALONE. SECOND, WE WILL DETERMINE IF ANY OF THE IC-SPECIFIC M.AB ARE SPECIFIC FOR CERTAIN ISOTYPES. THIRD, WE WILL DEMONSTRATE THAT THE EPITOPES RECOGNIZED BY THESE M.AB ARE DUE TO CONFORMATIONAL CHANGES IN THE BOUND ABAND NOT SIMPLY DUE TO AGGREGATION OR DIMER FORMATION. FINALLY, WE WILL BEGIN TO TEST THESE M.AB IN ASSAYS FOR IC IN SERA FROM MICE WITH AUTOIMMUNE DISEASE.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government